Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD pl... Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products. 더 보기
- On August 11, 2024, Revance and Crown Laboratories, Inc. entered into a merger agreement. As a result of discussions between the Revance and Teoxane, Crown and Revance agreed to extend the...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.05 | -1.25944584383 | 3.97 | 4.21 | 3.55 | 1927727 | 3.79788503 | CS |
4 | -1.88 | -32.4137931034 | 5.8 | 5.96 | 3.36 | 2635860 | 3.9523736 | CS |
12 | -2.65 | -40.3348554033 | 6.57 | 6.59 | 3.36 | 2943225 | 5.2657592 | CS |
26 | 1 | 34.2465753425 | 2.92 | 6.65 | 2.3 | 3344639 | 5.38105903 | CS |
52 | -3.29 | -45.6310679612 | 7.21 | 9.745 | 2.3 | 2593734 | 5.33554811 | CS |
156 | -10.9 | -73.5492577598 | 14.82 | 37.98 | 2.3 | 1706568 | 13.25879521 | CS |
260 | -15.85 | -80.1719777441 | 19.77 | 37.98 | 2.3 | 1286719 | 15.17255575 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관